Hemgenix® (etranacogene dezaparvovec) has been approved by the Italian Medicines Agency (AIFA). This decision marks a key milestone in access to therapeutic innovation in Italy.Â
Hemgenix was the first gene therapy to be approved in Europe for the treatment of severe and moderately severe haemophilia B in adult patients without a history of Factor IX inhibitors.
This milestone follows in the footsteps of groundbreaking reimbursement and access agreements reached in Spain, Switzerland, Germany, the UK (including Scotland), Denmark and Austria, paving the way for other European countries and beyond to implement innovative access solutions for gene therapies.
